GlassScriptPhysician profile
Ofelia C Balta
NPI 1912980178
$9,237.88
in general payments reported to CMS, 2019-2025
44 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $1,917 · 2021: $1,061 · 2022: $1,378 · 2023: $1,446 · 2024: $1,132 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,166.07 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,140.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.01 | 2019-2025 | Xifaxan |
| Amgen INC. | $610.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $563.00 | 2019-2025 | |
| Lilly USA, LLC | $538.16 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.94 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $441.91 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $421.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.32 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $317.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $278.70 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $252.08 | 2020-2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $239.22 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $225.41 | 2019-2023 | Xarelto |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofelia Balta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.